Microfluidics for the Production of Chitosan-TPP Nanoparticles: A Study using HMC chitosan
Microfluidics can precisely control the physiochemical properties of nanoparticles by mixing to the nanoliter. For this reason, nanoparticles for the transport of peptide drugs are to be developed in the study presented here with the help of chitosan from Heppe Medical Chitosan GmbH.
Peptide drugs offer a promising alternative to small molecule
drugs due to their high selectivity, efficacy and low toxicity. However,
peptide drugs can currently only be administered intravenously. In
order to enable non-invasive routes of administration, such as nasal,
oral or pulmonary, suitable drug delivery systems must be developed.
Polymer-based nanoparticles are particularly promising. They have many
advantages, e.g. good protection against premature degradation of the
active ingredient, more targeted transport, as well as improved
bioavailability and intracellular penetration.
Chitosan stands out as a material for this, as it also has good
biocompatibility, biodegradability, antibacterial and antioxidant
properties. Ionotrophic gelation is the most common method for producing
chitosan nanoparticles. Here, the positively charged chitosan is mixed
with another, negatively charged molecule such as tripolyphosphate (TPP)
and forms nanoparticles through a sol-gel transition. The conventional
bulk method often results in high batch-to-batch variations. This could
be avoided by using microfluidic chips. The physiochemical properties of
the nanoparticles can be controlled through the miniaturization of the
manufacturing process and the possibility of adding liquids in the
nanolitre range. In addition, manufacturing in microfluidic chips has
the advantage that nanoparticle properties can be optimized by
microfluidic parameters such as the total flow rate, the ratio of the
flows to each other and the chip geometry, and the scale-up is
simplified.
In the study presented here, a self-made 3D microfluidic chip will
be used for the production of chitosan TPP nanoparticles loaded with
argireline as a model cargo. The aim is to develop a suitable
transporter for peptide drugs by varying the flow rate in the chip, the
pH and the concentration of the chitosan. A chitosan with the
specification 80/20 from Heppe Medical Chitosan GmbH is used in the study. The nanoparticles were then embedded in a gel matrix to enable topical application.
RESULTS
- Chitosan concentration and pH have the greatest influence on particle size, while chitosan and TPP concentrations influence PDI → Best nanoparticle properties at pH 5, 2 mg/ml chitosan and 0.5 mg/ml TPP
- Entrapment efficiency of 90 % of argireline for the selected nanoparticle composition and a size of 186.0 ± 1.0 nm and a PDI of 0.440 ± 0.002
- Nanoparticles in gel matrix possessed suitable mechanical properties (e.g. hardness, compressibility, adhesiveness, cohesion and elasticity) for transdermal delivery of argireline
- Improved drug release over 48 h compared to free nanoparticles
Full article: https://www.sciencedirect.com/science/article/pii/S2666893924000045?via%3Dihub
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance